Company Snapshot
- Ticker
- INCY
- Name
- INCY
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 18668874700.000000
- Volume
- 2,264,451
- Avg Volume (3M)
- 2,063,642
INCY
INCY
Last update recent
95.41
-0.69
(-0.72%)
Market Cap
18668874700.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 4813104999.000000
- EPS
- 6.12
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- 1188583000.000000
- Net Margin
- 24.69%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- 15.71
- Forward P/E
- None
- P/S
- 3.88
- P/B
- 4.01
- Beta
- None
- Debt / Equity
- 0.01
- Current Ratio
- 3.19
- Return on Equity
- 0.26%
- Return on Assets
- 0.19%
Technicals & Returns
- Distance vs 200 DMA
- 23.7%
- 200 DMA
- 77.13
- Distance vs 50 DMA
- -1.17%
- 50 DMA
- 96.54
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-re Read more
- Name
- INCY
- Industry
- Biotechnology
- CEO
- Mr. Herve Hoppenot
- Employees
- 2,524
- IPO Date
- 1993-11-04
- Phone
- 302 498 6700
- Address
- None
- Website
- https://www.incyte.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
Incyte Announces Change to its Board of Directors
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Change to its Board of Directors.
Here's Why Incyte (INCY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH2025--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutC…
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Incyte's New Therapy Shows Signs Of 'Disease-Modifying' Potential In Rare Blood Cancer
Early ASH 2025 data shows Incyte's INCA033989 delivers spleen, anemia and symptom improvements in mutCALR myelofibrosis.
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY
First Trust Advisors LP reduced its position in shares of Incyte Corporation (NASDAQ: INCY) by 1.6% in the second quarter, according to its most recent filing …